Pds biotechnology corp (PDSB)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net income (loss)

-17,800

-6,998

-4,640

400

3,718

-3,836

-15,920

-26,490

-39,427

-50,859

-46,471

-45,949

-41,820

-38,820

-37,264

-36,635

-32,780

-28,078

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

509

3,139

3,711

3,588

3,614

866

1,595

3,168

4,704

6,182

5,912

5,575

5,375

5,305

5,362

4,740

3,943

2,899

0

0

0

Stock-based 401K company common match

46

37

29

25

0

0

46

95

95

217

170

121

121

0

0

0

0

-

-

-

-

Depreciation expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

69

110

147

182

174

155

127

100

75

61

59

53

0

0

0

Impairment of machinery and equipment

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

Bargain purchase gain

1,604

13,334

11,939

11,939

11,729

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Increase in warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,879

0

0

0

Amortization of debt discount

-

-

-

-

-

-

-

-

-

32

43

54

65

75

85

94

100

104

0

0

0

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

108

108

105

96

90

158

134

115

94

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

363

368

342

259

175

92

36

39

38

0

0

0

Changes in assets and liabilities:
Prepaid expenses and other assets

1,527

1,138

-1,839

-102

231

35

625

329

271

32

-33

-93

-142

-38

259

613

600

814

0

0

0

Accounts payable

1

-1,977

-976

-540

152

788

1,666

246

1,857

898

1,296

1,954

-365

1,420

-345

1,420

1,531

-71

0

0

0

Accrued expenses

0

-

0

0

0

-

2,286

1,496

2,193

2,208

860

2,545

2,007

-676

-931

196

-754

2,142

0

0

0

Restructuring reserve

-1,678

-1,572

-1,211

-786

-121

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-17,870

-18,073

-12,871

-8,975

-4,532

-1,569

-10,492

-21,459

-30,327

-40,696

0

0

0

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Cash received in reverse merger transaction

0

29,106

29,106

29,106

29,106

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-26,561

-

0

0

0

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

188

508

597

698

686

845

1,053

1,296

1,305

0

0

0

Net cash provided by investing activities

275

29,381

29,106

29,106

29,106

0

-27

-83

-99

-188

0

0

0

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,296

-

0

0

0

Proceeds from issuance of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

0

0

0

Proceeds from stock option exercise

-

-

-

-

-

-

-

-

-

118

91

359

344

293

295

27

1

1

0

0

0

Proceeds from exercise of warrants

0

-

-

-

0

-

-

-

-

53

58

22

24

20

0

0

0

-

-

-

-

Payments for issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

544

1,473

1,707

1,901

1,402

0

0

0

Payments for debt back end fees

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

Repayments of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

1,488

2,022

1,640

1,080

533

0

0

0

Proceeds from issuance of shares, gross

11,970

750

800

973

974

1,280

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of capital lease obligation

-

-

-

-

-

15

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

52,394

0

0

0

Net cash provided by financing activities

12,040

750

1,028

1,198

1,194

1,497

1,247

1,124

23,552

22,554

0

0

0

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-5,555

12,058

17,263

21,328

25,768

-72

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

135,504

-

0

0

0

Net decrease in cash

-

-

-

-

-

-

-

-

-

-18,331

-15,477

-2,307

-24,351

-23,790

59,904

52,556

107,646

116,460

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for:
Interest

-0

0

0

0

1

1

463

932

1,292

1,635

0

0

0

-

-

-

-

-

-

-

-

Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

587

-

0

0

0

Supplemental cash flow information:
Conversion of convertible notes and accrued interest into common stock

0

32

32

32

32

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Consideration in connection with reverse merger transaction

0

15,793

15,793

15,793

15,793

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred issuance costs included in accrued expenses and accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

549

0

0

0

Accrued capital expenditures included in accrued expenses and accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

167

-157

334

-6

71

0

0

0